Physician profile
Robert E Leininger
NPI 1902068059
$5,315.18
in general payments reported to CMS, 2019-2025
22 companies · $984 in 2025
The $984 reported for 2025 was more than what 78% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $792 · 2020: $620 · 2021: $714 · 2022: $847 · 2023: $685 · 2024: $673 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,322.46 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $726.47 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Merck Sharp & Dohme LLC | $702.11 | 2019-2025 | Pifeltro, Dificid, Delstrigo |
| Abbvie INC. | $490.25 | 2019-2025 | |
| Janssen Biotech, INC. | $415.03 | 2019-2023 | Symtuza |
| Melinta Therapeutics, LLC | $399.90 | 2019-2023 | Vabomere, Orbactiv, Kimyrsa |
| Aimmune Therapeutics, INC. | $255.42 | 2023-2025 | Vowst |
| Astellas Pharma US INC | $170.02 | 2021-2025 | Cresemba |
| La Jolla Pharmaceutical Company | $109.91 | 2020-2024 | Xerava |
| Insmed, INC. | $109.42 | 2020-2025 | Arikayce |
| Theratechnologies INC. | $95.61 | 2019-2025 | Trogarzo, Egrifta |
| Shionogi INC | $92.10 | 2021-2025 | Fetroja |
| Allergan, INC. | $85.89 | 2019-2020 | |
| Janssen Products, LP | $85.00 | 2021 | |
| Ferring Pharmaceuticals INC. | $57.02 | 2022-2025 | Rebyota |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tetraphase Pharmaceuticals, INC. | $53.37 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $44.46 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $41.18 | 2019-2025 | Vibativ |
| Adma Biomanufacturing LLC | $22.74 | 2021 | |
| Pfizer INC. | $14.13 | 2024 | |
| Nabriva Therapeutics, Plc | $11.86 | 2020 | |
| Romark Laboratories, Lc | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Leininger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.